Strategic Consideration to Leverage the Translatability From Preclinical Assessments to Clinical Trial Through Implementation of Appropriate Assays

Time: 9:00 am
day: Day Two AM


  • In vitro cytokine release assay in hPBMC and in vivo toxicity assessment with characterization of drug exposure
  • Immune response under repeated dosing modality of PEGylated LNP through systemic delivery and mitigation strategies
  • Regulatory perspective of toxicity assessment on the LNP with different API entities